CTLA4-Ig fusion protein (Asklepios BioPharmaceutical/University of North Carolina)

N/A

Report date: 2025/03/18 18:14:04

Base Information

Drug NameCTLA4-Ig fusion protein (Asklepios BioPharmaceutical/University of North Carolina)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCluster of differentiation 86 inhibitorsCluster of differentiation 80 inhibitors
TargetsCluster of differentiation 86Cluster of differentiation 80
Therapy Area/IndicationsImmune System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUnc
China Registration ClassN/A

Develop Information

Active CompaniesAskBio IncUnc
Inactive CompaniesN/A
Active IndicationsImmune System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A